Cover Image
市場調查報告書

肺癌疫苗的全球市場和開發平台(管線)分析 (2015年)

Global Lung Cancer Vaccine Market & Pipeline Insight 2015

出版商 KuicK Research 商品編碼 324798
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肺癌疫苗的全球市場和開發平台(管線)分析 (2015年) Global Lung Cancer Vaccine Market & Pipeline Insight 2015
出版日期: 2015年02月24日 內容資訊: 英文 120 Pages
簡介

隨著世界各國肺癌患者數的增加,也開發及應用出各種治療法。由於外科手術及放射線治療不適合用於肺癌治療,而以化療及標的療法為主體,前者副作用高,後者則是「治療效果雖好但卻未改善死亡率」。同時隨著腫瘤機制及抗原相關究的進行,也開發出利用MAGE-3抗原的肺癌疫苗。目前許多企業都致力於開發、實驗肺癌疫苗,同時也隨著其安全性及有效性的確認與否而在世界各國一一準備上市。

本報告提供全球各國肺癌疫苗市場趨勢,及開發平台產品的開發情形相關分析,提供肺癌疫苗概要·特性·作用機制,及癌症疫苗整體及肺癌疫苗到目前為止的開發流程,開發中產品的目前開發情形,產品單位 (計29產品) 的詳細開發情形,已上市產品 (計3產品) 銷售情形,今後的市場方向性等資訊,為您概述為以下內容。

第1章 癌症疫苗的概要

第2章 癌症疫苗:作用機制 (機制) 與創新

  • 個體遺傳型癌症疫苗的作用機制
  • 細胞性癌症疫苗的作用機制
  • 基於醣脂化合物的癌症疫苗作用機制
  • 胜肽癌症疫苗的作用機制
  • 腫瘤宿主關係癌症疫苗的作用機制

第3章 肺癌疫苗的概要

第4章 肺癌疫苗的作用機制

第5章 肺癌疫苗的全球市場預測

  • 目前市場方案
  • 肺癌疫苗的開發中產品概要

第6章 肺癌的全球市場動態

  • 有助於市場的指標
  • 市場·商業化相關課題

第7章 肺癌疫苗的全球市場未來展望

第8章 肺癌疫苗的全球市場開發中產品:各企業·代 (Phase) 別

  • 前臨床階段
  • 臨床階段
  • 第一階段
  • 第I/II相
  • 第二階段
  • 第II/III相
  • 第三階段

第9章 已上市的肺癌疫苗的臨床性考察

  • BV NSCLC 001
  • Mycidac-C™
  • Vaxira®

第10章 臨床實驗延期·中斷的肺癌疫苗的開發中產品:各企業·Phase別

  • 無臨床實驗資訊
  • 臨床實驗中斷

第11章 競爭環境

  • Boehringer Ingelheim
  • CureVac
  • Eli Lily
  • Galaxo
  • ImClone Systems
  • Merck
  • 小野藥品工業
  • Oncothyreon Incorporation

圖表一覽

目錄

Lung cancer incidences are rapidly increasing and various therapeutics have been introduced in global market to provide better care to patients. Surgery and radiation therapy are not preferred for lung cancer treatment due to which they have small global market size. Chemotherapeutics and targeted therapeutics for lung cancer treatment are major market contender in global market with wide acceptance levels among oncologists and patients. Chemotherapeutics have life threatening side effects while targeted therapeutics available in markets are quite effective therapeutics but they are unable to reduce the present lung cancer mortality rates. These drawbacks are not expected to be associated with lung cancer vaccines which will help in generating significant revenues and increased penetration across the globe.

Identification of novel targets for lung cancer vaccine development is underway by pharmaceutical companies to provide efficient medical care to patients. Many mechanisms and tumour antigen has been identified for the development of novel lung cancer vaccines. Different lung cancer vaccines will help the patients in deciding better therapeutic options and generate significant revenues for pharmaceutical companies. Pharmacological effects provided by these novel lung cancer vaccine is expected to help the lung cancer patients across the globe.

Melanoma associated antigen 3(MAGE-3) is target of various cancer vaccines for therapeutic treatment of lung cancer. This antigen is absent in normal cell, while it is abundantly found in cancerous cells making it a suitable candidate for developing lung cancer vaccine targeting different stages of cancer progression. These lung cancer vaccines are able to identify different levels of MAGE-3 leading to their correct identification. As a result, cancer vaccine targeting this antigen is expected to have minimized side effects because it is absent in normal cell. This fact also shows that relapse may not occur due to eradication of all existing cancerous cells from the body.

Lung cancer vaccine is formulated by incorporating MAGE-3 antigen as source of activation for immune cells. This vaccine consists of fusion between human MAGE-3 antigen and protein D from Haemophilus influnzae. When it is injected inside the body it causes the immune system to get activated and identify this formulation as external entity. This causes the memory cells to search for any external substances in body having signature sequences like vaccines. As a result, cancerous cells present in the body are identified as external entity and selectively eliminated to prevent the cancer progression.

Lung cancer vaccines are expected to become a major tool in lung cancer treatment in coming years due to superior pharmacological performance. Prophylactic lung cancer vaccines are needed to be developed and thoroughly investigated in clinical trilas. Many innovative lung cancer vaccines are under various phases of clinical trials effective medical treatment. Significant clinical data generated has given encouragement to oncologists and pharmaceutical companies to investigate different forms of lung cancer vaccine. These vaccines are under investigation, once high safety and efficacy levels are obtained then it would be easy to apply for the marketing approval across the globe in various countries.

"Global Lung Cancer Vaccine Market & Pipeline Insight 2015" Report Highlights:

  • Introduction to Lung Cancer Vaccine
  • Global Lung Cancer Vaccine Market Analysis
  • Global Lung Cancer Vaccine Pipeline by Company & Phase
  • Global Lung Cancer Vaccine Pipeline: 29 Vaccines
  • Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines
  • Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C & Vaxira)
  • Personalized Cancer Vaccines: Progress & Possibilities
  • Lung Cancer Vaccine Mechanism

Table of Contents

1. Introduction to Cancer Vaccines

2. Cancer Vaccines: Mechanism & Innovations

  • 2.1 Idiotype Cancer Vaccine Mechanism
  • 2.2 Cellular Cancer Vaccines Mechanism
  • 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
  • 2.4 Peptide Cancer Vaccine Mechanism
  • 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Introduction Global Lung Cancer Vaccine

4. Mechanism of Lung Cancer Vaccines

5. Global Lung Cancer Vaccine Market Outlook

  • 5.1 Current Market Scenario
  • 5.2 Global Lung Cancer Vaccines Pipeline Overview

6. Global Lung Cancer Market Dynamics

  • 6.1 Favorable Market Parameters
  • 6.2 Market & Commercialization Challenges

7. Global Lung Cancer Vaccine Market Future Prospects

8. Global Lung Cancer Vaccine Pipeline by Company & Phase

  • 8.1 Preclinical
  • 8.2 Clinical
  • 8.3 Phase-I
  • 8.4 Phase-I/II
  • 8.5 Phase-II
  • 8.6 Phase-II/III
  • 8.7 Phase-III

9. Marketed Lung Cancer Vaccine Clinical Insight

  • 9.1 BV NSCLC 001
  • 9.2 Mycidac-C™
  • 9.3 Vaxira®

10. Suspended & Discontinued Lung Cancer Vaccines Pipeline by Company & Phase

  • 10.1 No Development Reported
  • 10.2 Discontinued

11. Competitive Landscape

  • 11.1 Boehringer Ingelheim
  • 11.2 CureVac
  • 11.3 Eli Lily
  • 11.4 Galaxo
  • 11.5 ImClone Systems
  • 11.6 Merck
  • 11.7 Ono Pharmaceutical
  • 11.8 Oncothyreon Incorporation

List of Figures

  • Figure 1-1: Categorization & Function of Cancer Vaccines
  • Figure 2-1: Classification of Different Types of Cancer vaccines
  • Figure 3-1: Functions of Lungs
  • Figure 3-2: Factors Responsible for Increasing Lung Cancer Incidences
  • Figure 4-1: Type of Lung Cancer
  • Figure 4-2: Types of Lung Cancer Treatment
  • Figure 4-3: Mechanism of MAGE-3 Lung Cancer Vaccine
  • Figure 4-4: Mechanism of p53 Lung Cancer Vaccine
  • Figure 4-5: Mechanism of NY-ESO-1 Lung Cancer Vaccine
  • Figure 5-1: Global Lung Cancer Vaccines Pipeline (%), 2015
  • Figure 5-2: Global Lung Cancer Vaccines Pipeline (Number), 2015
  • Figure 5-3: No Development Reported in Lung Cancer Vaccines Pipeline (%), 2015
  • Figure 5-4: No Development Reported in Lung Cancer Vaccines Pipeline (Number), 2015
  • Figure 5-5: Discontinued Lung Cancer Vaccines Pipeline (%), 2015
  • Figure 5-6: Discontinued Lung Cancer Vaccines Pipeline (Number), 2015
  • Figure 6-1: Drivers for Lung Cancer Vaccines
  • Figure 6-2: Market & Commercialization Challenges
Back to Top